Crinetics Pharmaceuticals, Inc. (CRNX) announced pricing of upsized underwritten public offering of 10 million common shares at $50.00 per share. The offering is expected to close on or about October 10, 2024.
Crinetics also granted the underwriters a 30-day option to purchase up to an additional 1.5 million common shares. The company expects offering gross proceeds, before expenses, to be $500.0 million.
Crinetics intends to use offering net proceeds, together with cash, cash equivalents and investment securities, to fund research and development, other research programs, pre-commercialization activities and other general corporate purposes.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.